$elv 2019 10-K

Concept	2019	2018 Q4	2018 Q3
Revenue	$104.2B	$23.37B	$23.25B
YoY Change	13.15%	3.05%	3.68%
Cost Of Revenue	$1.992B		$0.00
YoY Change			-100.0%
Gross Profit	$102.2B		$23.25B
YoY Change	10.98%		437.97%
Gross Profit Margin	98.09%		100.0%
Selling, General & Admin	$13.36B	$3.618B	$3.546B
YoY Change	-4.68%	6.63%	17.77%
% of Gross Profit	13.07%		15.25%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$147.0M	$288.0M	$288.0M
YoY Change	18.55%	26.87%	29.15%
% of Gross Profit	0.14%		1.24%
Operating Expenses	$13.36B	$22.65B	$3.546B
YoY Change	-4.68%	2.43%	17.77%
Operating Profit	$5.999B		$1.249B
YoY Change	10.56%		27.19%
Interest Expense	$746.0M	-$189.0M	$188.0M
YoY Change	-0.93%	15.24%	25.33%
% of Operating Profit	12.44%		15.05%
Other Income/Expense, Net
YoY Change
Pretax Income	$5.985B	$542.0M	$1.242B
YoY Change	18.09%	330.16%	10.99%
Income Tax	$1.178B	$146.0M	$282.0M
% Of Pretax Income	19.68%	26.94%	22.71%
Net Earnings	$4.807B	$424.0M	$960.0M
YoY Change	28.19%	-65.58%	28.51%
Net Earnings / Revenue	4.61%	1.81%	4.13%
Basic Earnings Per Share	$18.81	$1.64	$3.70
Diluted Earnings Per Share	$18.47	$1.61	$3.62
COMMON SHARES
Basic Shares Outstanding	255.5M shares	258.6M shares	259.5M shares
Diluted Shares Outstanding	260.3M shares		265.4M shares

Concept	2019	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$20.63B	$21.65B
YoY Change		-1.72%	-12.68%
Cash & Equivalents	$4.937B	$3.934B	$4.260B
Short-Term Investments		$16.69B	$17.39B
Other Short-Term Assets		$2.104B	$2.875B
YoY Change		-6.45%	57.79%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$34.32B	$37.11B
YoY Change		-5.36%	0.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.708B	$2.735B	$2.592B
YoY Change	35.58%	25.75%	26.49%
Goodwill		$20.50B	$20.47B
YoY Change		6.62%	16.38%
Intangibles		$9.007B	$9.101B
YoY Change		7.64%	16.08%
Long-Term Investments	$25.46B	$22.45B	$23.79B
YoY Change	13.4%	-9.94%	2.63%
Other Assets	$353.0M	$758.0M	$1.074B
YoY Change	-41.56%	34.16%	26.22%
Total Long-Term Assets		$37.25B	$37.34B
YoY Change		8.67%	19.15%
TOTAL ASSETS
Total Short-Term Assets		$34.32B	$37.11B
Total Long-Term Assets		$37.25B	$37.34B
Total Assets	$77.45B	$71.57B	$74.45B
YoY Change	8.22%	1.46%	8.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.198B	$4.959B	$6.286B
YoY Change	-15.35%	-1.29%	41.13%
Accrued Expenses	$640.0M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$700.0M	$1.145B	$1.270B
YoY Change	-38.86%	-10.2%	7.63%
Long-Term Debt Due	$1.598B	$849.0M	$849.0M
YoY Change	88.22%	-33.41%	-33.33%
Total Short-Term Liabilities	$7.571B	$21.97B	$24.17B
YoY Change	-2.36%	-5.96%	-0.98%
LONG-TERM LIABILITIES
Long-Term Debt	$17.79B	$17.22B	$17.30B
YoY Change	3.31%	-0.95%	25.57%
Other Long-Term Liabilities	$4.472B	$1.182B	$1.145B
YoY Change	2.29%	27.78%	21.29%
Total Long-Term Liabilities	$22.26B	$18.40B	$18.45B
YoY Change	3.1%	0.5%	25.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.571B	$21.97B	$24.17B
Total Long-Term Liabilities	$22.26B	$18.40B	$18.45B
Total Liabilities	$45.73B	$43.03B	$45.35B
YoY Change	6.26%	-2.29%	7.06%
SHAREHOLDERS EQUITY
Retained Earnings		$19.99B	$20.18B
YoY Change		10.71%	16.61%
Common Stock		$3.000M	$3.000M
YoY Change		0.0%	15.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.73B	$28.54B	$29.09B
YoY Change
Total Liabilities & Shareholders Equity	$77.45B	$71.57B	$74.45B
YoY Change	8.22%	1.46%	8.98%

Concept	2019	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	$4.807B	$424.0M	$960.0M
YoY Change	28.19%	-65.58%	28.51%
Depreciation, Depletion And Amortization	$147.0M	$288.0M	$288.0M
YoY Change	18.55%	26.87%	29.15%
Cash From Operating Activities	$6.061B	$463.0M	$607.0M
YoY Change	58.37%	-135.59%	-74.76%
INVESTING ACTIVITIES
Capital Expenditures	$1.077B	-$320.0M	-$355.0M
YoY Change	-10.84%	12.68%	62.84%
Acquisitions	$0.00
YoY Change	-100.0%
Other Investing Activities	$50.00M	$1.093B	-$332.0M
YoY Change	-29.58%	-132.75%	-132.39%
Cash From Investing Activities	-$2.792B	$773.0M	-$688.0M
YoY Change	121.76%	-121.35%	-185.25%
FINANCING ACTIVITIES
Cash Dividend Paid	$818.0M	$193.0M	$195.0M
YoY Change	5.41%	7.22%	7.73%
Common Stock Issuance & Retirement, Net	$1.701B
YoY Change	291.03%
Debt Paid & Issued, Net	$1.123B
YoY Change	-33.31%
Cash From Financing Activities	-$2.266B	-1.561B	-341.0M
YoY Change	1.12%	-164.16%	-79.65%
NET CHANGE
Cash From Operating Activities	$6.061B	463.0M	607.0M
Cash From Investing Activities	-$2.792B	773.0M	-688.0M
Cash From Financing Activities	-$2.266B	-1.561B	-341.0M
Net Change In Cash	$1.003B	-325.0M	-422.0M
YoY Change	208.62%	-86.94%	-127.47%
FREE CASH FLOW
Cash From Operating Activities	$6.061B	$463.0M	$607.0M
Capital Expenditures	$1.077B	-$320.0M	-$355.0M
Free Cash Flow	$4.984B	$783.0M	$962.0M
YoY Change	90.3%	-176.99%	-63.32%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q4	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	486000000	USD
CY2019Q4	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	487000000	USD
CY2017	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	35000000	USD
CY2018	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-29000000	USD
CY2019	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	9000000	USD
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001156039
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16894000000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19021000000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	257395577	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	252922161	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	257395577	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	252922161	shares
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	153000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	13000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-133000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	198000000	USD
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46204
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2019	dei	City Area Code CityAreaCode	(800)
CY2019	dei	Local Phone Number LocalPhoneNumber	331-1476
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-58000000	USD
CY2019	dei	Trading Symbol TradingSymbol	ANTM
CY2019	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-4000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	99000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-140000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	199000000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-35000000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	10000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-4000000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities	3000000	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities	-1000000	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-16751
CY2019	dei	Entity Registrant Name EntityRegistrantName	ANTHEM, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IN
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2145715
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	220 Virginia Avenue
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Indianapolis
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q4	us-gaap	Assets Assets	77453000000	USD
CY2018Q4	us-gaap	Assets Assets	71571000000	USD
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	3726000000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3133000000	USD
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	72160040688	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2735000000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	20500000000	USD
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	252329919	shares
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3934000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	19676000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	16692000000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1009000000	USD
CY2018Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1493000000	USD
CY2019Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	13000000	USD
CY2018Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	21000000	USD
CY2019Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	173000000	USD
CY2018Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	162000000	USD
CY2019Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5173000000	USD
CY2018Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	4465000000	USD
CY2019Q4	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2411000000	USD
CY2018Q4	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2278000000	USD
CY2019Q4	us-gaap	Other Receivables OtherReceivables	2634000000	USD
CY2018Q4	us-gaap	Other Receivables OtherReceivables	2558000000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	335000000	USD
CY2018Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10000000	USD
CY2019Q4	us-gaap	Securities Received As Collateral SecuritiesReceivedAsCollateral	353000000	USD
CY2018Q4	us-gaap	Securities Received As Collateral SecuritiesReceivedAsCollateral	604000000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2319000000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2104000000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	39033000000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	34321000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	505000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	487000000	USD
CY2019Q4	antm	Equitysecurities Longterm EquitysecuritiesLongterm	30000000	USD
CY2018Q4	antm	Equitysecurities Longterm EquitysecuritiesLongterm	33000000	USD
CY2019Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	4228000000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	20504000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8674000000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9007000000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1350000000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	758000000	USD
CY2019Q4	antm	Liability For Future Policy Benefits Current LiabilityForFuturePolicyBenefitsCurrent	85000000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	antm	Liability For Future Policy Benefits Current LiabilityForFuturePolicyBenefitsCurrent	75000000	USD
CY2019Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	3050000000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	8842000000	USD
CY2018Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	7454000000	USD
CY2018Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	2590000000	USD
CY2019Q4	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	11977000000	USD
CY2018Q4	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	10119000000	USD
CY2019Q4	us-gaap	Unearned Premiums UnearnedPremiums	1017000000	USD
CY2018Q4	us-gaap	Unearned Premiums UnearnedPremiums	902000000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4198000000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4959000000	USD
CY2019Q4	srt	Payables To Broker Dealers And Clearing Organizations PayablesToBrokerDealersAndClearingOrganizations	84000000	USD
CY2018Q4	srt	Payables To Broker Dealers And Clearing Organizations PayablesToBrokerDealersAndClearingOrganizations	197000000	USD
CY2019Q4	us-gaap	Deposits Received For Securities Loaned At Carrying Value DepositsReceivedForSecuritiesLoanedAtCarryingValue	351000000	USD
CY2018Q4	us-gaap	Deposits Received For Securities Loaned At Carrying Value DepositsReceivedForSecuritiesLoanedAtCarryingValue	604000000	USD
CY2019Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	700000000	USD
CY2018Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1145000000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1598000000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	849000000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3692000000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3190000000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23617000000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21965000000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17787000000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17217000000	USD
CY2019Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	674000000	USD
CY2018Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	706000000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2227000000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1960000000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1420000000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1182000000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	45725000000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	43030000000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9448000000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9536000000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	22573000000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	19988000000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-296000000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-986000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	31728000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	28541000000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77453000000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71571000000	USD
CY2019	us-gaap	Premiums Earned Net PremiumsEarnedNet	94173000000	USD
CY2018	us-gaap	Premiums Earned Net PremiumsEarnedNet	85421000000	USD
CY2017	us-gaap	Premiums Earned Net PremiumsEarnedNet	83648000000	USD
CY2019	us-gaap	Other Income OtherIncome	8968000000	USD
CY2018	us-gaap	Other Income OtherIncome	5920000000	USD
CY2017	us-gaap	Other Income OtherIncome	5413000000	USD
CY2019	antm	Operating Revenue OperatingRevenue	103141000000	USD
CY2018	antm	Operating Revenue OperatingRevenue	91341000000	USD
CY2017	antm	Operating Revenue OperatingRevenue	89061000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1005000000	USD
CY2018	us-gaap	Net Investment Income NetInvestmentIncome	970000000	USD
CY2017	us-gaap	Net Investment Income NetInvestmentIncome	867000000	USD
CY2019	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	114000000	USD
CY2018	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	-180000000	USD
CY2017	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	145000000	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	53000000	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	29000000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	35000000	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	-6000000	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	-3000000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	-2000000	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	47000000	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	26000000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	33000000	USD
CY2019	us-gaap	Revenues Revenues	104213000000	USD
CY2018	us-gaap	Revenues Revenues	92105000000	USD
CY2017	us-gaap	Revenues Revenues	90040000000	USD
CY2019	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	81786000000	USD
CY2018	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	71895000000	USD
CY2017	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	72236000000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1992000000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13364000000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14020000000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12650000000	USD
CY2019	us-gaap	Interest Expense InterestExpense	746000000	USD
CY2018	us-gaap	Interest Expense InterestExpense	753000000	USD
CY2017	us-gaap	Interest Expense InterestExpense	739000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	338000000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	358000000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	169000000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2000000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-11000000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-282000000	USD
CY2019	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	98228000000	USD
CY2018	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	87037000000	USD
CY2017	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	86076000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5985000000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5068000000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3964000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1178000000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1318000000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	121000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3750000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	3843000000	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	18.81
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.53
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.70
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	18.47
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	14.19
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	14.35
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.20
CY2018	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.00
CY2017	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.70
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3750000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	3843000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	680000000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-418000000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	173000000	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	81000000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	91000000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1272000000	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities	2000000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities	-4000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-16000000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	37000000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-65000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-26000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	90000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-51000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-474000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	166000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5497000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3276000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4009000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3750000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	3843000000	USD
CY2019	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	114000000	USD
CY2018	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	-180000000	USD
CY2017	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	145000000	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	47000000	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	26000000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	33000000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2000000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-11000000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-282000000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13000000	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-15000000	USD
CY2019	us-gaap	Adjustment For Amortization AdjustmentForAmortization	986000000	USD
CY2018	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1008000000	USD
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	780000000	USD
CY2019	us-gaap	Depreciation Depreciation	147000000	USD
CY2018	us-gaap	Depreciation Depreciation	124000000	USD
CY2017	us-gaap	Depreciation Depreciation	111000000	USD
CY2017	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	22000000	USD
CY2019	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	48000000	USD
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1053000000	USD
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	695000000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	6442000000	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	7932000000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	294000000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	226000000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	170000000	USD
CY2018	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	1000000	USD
CY2017	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	36000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	170000000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	26000000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	629000000	USD
CY2019	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1826000000	USD
CY2018	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-1059000000	USD
CY2017	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	732000000	USD
CY2019	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	115000000	USD
CY2018	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-36000000	USD
CY2017	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-120000000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-593000000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	122000000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	922000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	148000000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-25000000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-120000000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-325000000	USD
CY2018	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	323000000	USD
CY2017	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-194000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	92000000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	205000000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	165000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6061000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3827000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4185000000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10487000000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	8244000000	USD
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9795000000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5914000000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2437000000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1938000000	USD
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1848000000	USD
CY2019	antm	Paymentstoacquireequitysecurities Paymentstoacquireequitysecurities	11825000000	USD
CY2018	antm	Paymentstoacquireequitysecurities Paymentstoacquireequitysecurities	896000000	USD
CY2017	antm	Paymentstoacquireequitysecurities Paymentstoacquireequitysecurities	5416000000	USD
CY2019	antm	Proceedsfromsaleofequitysecurities Proceedsfromsaleofequitysecurities	12364000000	USD
CY2018	antm	Proceedsfromsaleofequitysecurities Proceedsfromsaleofequitysecurities	2809000000	USD
CY2017	antm	Proceedsfromsaleofequitysecurities Proceedsfromsaleofequitysecurities	3463000000	USD
CY2019	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	642000000	USD
CY2018	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	531000000	USD
CY2017	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1164000000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	320000000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	411000000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	219000000	USD
CY2019	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	0	USD
CY2018	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	0	USD
CY2017	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	-65000000	USD
CY2019	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	-254000000	USD
CY2018	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	149000000	USD
CY2017	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	-625000000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1760000000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2080000000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1077000000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1208000000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	791000000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	50000000	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	71000000	USD
CY2017	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-12000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2792000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1259000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5082000000	USD
CY2019	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-297000000	USD
CY2018	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-107000000	USD
CY2017	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	175000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2473000000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	835000000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5458000000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1123000000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1684000000	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2815000000	USD
CY2019	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	7590000000	USD
CY2018	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	9120000000	USD
CY2017	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	5835000000	USD
CY2019	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	8035000000	USD
CY2018	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	9250000000	USD
CY2017	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	5000000000	USD
CY2019	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	-254000000	USD
CY2018	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	150000000	USD
CY2017	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	-625000000	USD
CY2019	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	-169000000	USD
CY2018	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	-210000000	USD
CY2017	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	71000000	USD
CY2019	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	1000000	USD
CY2018	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	USD
CY2017Q1	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	USD
CY2019	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	0	USD
CY2018	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	1000000	USD
CY2017	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	1000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1250000000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1701000000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1685000000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1998000000	USD
CY2019	antm	Payments For Proceeds From Financing Derivatives PaymentsForProceedsFromFinancingDerivatives	34000000	USD
CY2018	antm	Payments For Proceeds From Financing Derivatives PaymentsForProceedsFromFinancingDerivatives	-23000000	USD
CY2017	antm	Payments For Proceeds From Financing Derivatives PaymentsForProceedsFromFinancingDerivatives	149000000	USD
CY2019	us-gaap	Payments Of Dividends PaymentsOfDividends	818000000	USD
CY2018	us-gaap	Payments Of Dividends PaymentsOfDividends	776000000	USD
CY2017	us-gaap	Payments Of Dividends PaymentsOfDividends	705000000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	187000000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	173000000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	225000000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	84000000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	81000000	USD
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	46000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2266000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2241000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	427000000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2000000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	4000000	USD
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1003000000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	325000000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-466000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3934000000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3609000000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4075000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3934000000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3609000000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	25101000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	3843000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	166000000	USD
CY2017	antm	Net Adjustment To Additional Paid In Capital For Equity Hedge NetAdjustmentToAdditionalPaidInCapitalForEquityHedge	1000000	USD
CY2017	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1998000000	USD
CY2017	us-gaap	Dividends Common Stock DividendsCommonStock	707000000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	342000000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-245000000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	26503000000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	26503000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3750000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-474000000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1250000000	USD
CY2018	antm	Net Adjustment To Additional Paid In Capital For Equity Hedge NetAdjustmentToAdditionalPaidInCapitalForEquityHedge	1000000	USD
CY2018	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1685000000	USD
CY2018	us-gaap	Dividends Common Stock DividendsCommonStock	785000000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	318000000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-337000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	28541000000	USD
CY2018Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	26000000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	28567000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	690000000	USD
CY2019	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1701000000	USD
CY2019	us-gaap	Dividends Common Stock DividendsCommonStock	822000000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	396000000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-209000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	31728000000	USD
CY2019	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. </span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately </span><span style="font-family:inherit;font-size:10pt;"><span>41</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">medical members through our affiliated health plans as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs;</span><span style="font-family:inherit;font-size:10pt;"> Health Maintenance Organizations, or HMOs; Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as pharmacy benefits management, or PBM, dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits, or FEHB, Program. </span></div><span style="font-family:inherit;font-size:10pt;">We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York)</span><span style="font-family:inherit;font-size:10pt;">, Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states across the country as Aim Specialty Health, Amerigroup, Aspire Health, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or UniCare. Also, in the second quarter of 2019, we began providing PBM services through our IngenioRx subsidiary.</span><span style="font-family:inherit;font-size:10pt;"> We are licensed to conduct insurance operations in all </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>50</span></span><span style="font-family:inherit;font-size:10pt;"> states and the District of Columbia through our subsidiaries.</span>
CY2019Q4	antm	Number Of Medical Members NumberOfMedicalMembers	41000000	medical_member
CY2019Q4	antm	Number Of Counties In Geographical Region Not Served NumberOfCountiesInGeographicalRegionNotServed	30	counties
CY2019Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	50	states
CY2019	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications:</span><span style="font-family:inherit;font-size:10pt;"> Certain prior year amounts have been reclassified to conform to the current year presentation.</span></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates:</span><span style="font-family:inherit;font-size:10pt;"> The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>
CY2019Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	215000000	USD
CY2018Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	222000000	USD
CY2019	antm	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.02
CY2019Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	237000000	USD
CY2019Q4	antm	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	46000000	USD
CY2018Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	278000000	USD
CY2018Q4	antm	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	47000000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	242000000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	280000000	USD
CY2019	us-gaap	Defined Benefit Plan Alternative Method Used To Amortize Net Gains And Losses DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses	We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.
CY2018Q4	antm	Patient Protection Affordable Care Act Health Insurance Provider Fee PatientProtectionAffordableCareActHealthInsuranceProviderFee	14300000000	USD
CY2018	antm	Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid	1544000000	USD
CY2019	antm	Reserves For Future Policy Benefits Maximum Payable Period ReservesForFuturePolicyBenefitsMaximumPayablePeriod	P1Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.90
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	467000000	USD
CY2018	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	385000000	USD
CY2017	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	338000000	USD
CY2018Q1	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1 NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1	91000000	USD
CY2017	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Net Income NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome	36000000	USD
CY2017	antm	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Per Share Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPerShareAmount	0.13
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	320000000	USD
CY2019	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted: </span><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,</span><span style="font-family:inherit;font-size:10pt;"> or ASU 2019-12. The amendments in ASU 2019-12 remove certain exceptions to the general principles in ASC Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We are currently evaluating the effects the adoption of ASU 2019-12 will have on our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2019, the FASB issued Accounting Standards Update No. 2019-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="font-family:inherit;font-size:10pt;">. In May 2019, the FASB issued Accounting Standards Update No. 2019-05, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief</span><span style="font-family:inherit;font-size:10pt;">. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">. In November 2018, the FASB issued Accounting Standards Update No. 2018-19, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="font-family:inherit;font-size:10pt;">. These updates provide an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost and provide additional clarification and implementation guidance on certain aspects of the previously issued Accounting Standards Update No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="font-family:inherit;font-size:10pt;"> or ASU 2016-13, and have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 introduces a current expected credit loss model for measuring expected credit losses for certain types of financial instruments </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">held at the reporting date based on historical experience, current conditions and reasonable supportable forecasts. ASU 2016-13 replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities and provides for additional disclosure requirements. ASU 2016-13 requires a cumulative-effect adjustment to the opening balance of retained earnings on the statement of financial position at the date of adoption and a prospective transition approach for debt securities for which an OTTI had been recognized before the adoption date. The effect of a prospective transition approach is to maintain the same amortized cost basis before and after the date of adoption. We adopted ASU 2016-13 on January 1, 2020, and the adoption did not have a material impact on our beginning retained earnings or on our consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2018-15. The amendments in ASU 2018-15 require implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The amendments also require an entity to disclose the nature of its hosting arrangements and adhere to certain presentation requirements in its balance sheet, income statement and statement of cash flows. We adopted ASU 2018-15 on January 1, 2020 using a prospective approach for all implementation costs incurred after the date of adoption, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Retirement Benefits—Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2018-14. The amendments in ASU 2018-14 eliminate, add and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective basis to all periods presented. We are currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Services Insurance (Topic</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">944): Targeted Improvements to the Accounting for Long-Duration Contracts, </span><span style="font-family:inherit;font-size:10pt;">or ASU 2018-12. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments in ASU 2018-12 will be effective for our interim and annual reporting periods beginning after December 15, 2021. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued Accounting Standards Update No. 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2017-04. This update removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. Upon adoption, the guidance is to be applied prospectively. We adopted ASU 2017-04 on January 1, 2020, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no other new accounting pronouncements that were issued or became effective during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> that had, or are expected to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.</span></div>
CY2019Q4	antm	Merger Agreement Termination Fee MergerAgreementTerminationFee	1850000000	USD
CY2019Q4	antm	Equity Securities EquitySecurities	1039000000	USD
CY2018Q4	antm	Equity Securities EquitySecurities	1526000000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	1034000000	USD
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	1011000000	USD
CY2017	us-gaap	Investment Income Net InvestmentIncomeNet	908000000	USD
CY2019	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	29000000	USD
CY2018	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	41000000	USD
CY2017	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	41000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1005000000	USD
CY2018	us-gaap	Net Investment Income NetInvestmentIncome	970000000	USD
CY2017	us-gaap	Net Investment Income NetInvestmentIncome	867000000	USD
CY2019	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	131000000	USD
CY2018	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-203000000	USD
CY2017	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	200000000	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	47000000	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	26000000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	33000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	874000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-524000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	257000000	USD
CY2019	antm	Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments	194000000	USD
CY2018	antm	Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments	-106000000	USD
CY2017	antm	Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments	84000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	680000000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-418000000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	173000000	USD
CY2019	antm	Net Realized Gains Losses On Investments Other Than Temporary Impairment Losses Recognized In Income And Net Change In Net Unrealized Gains Losses On Investments NetRealizedGainsLossesOnInvestmentsOtherThanTemporaryImpairmentLossesRecognizedInIncomeAndNetChangeInNetUnrealizedGainsLossesOnInvestments	764000000	USD
CY2018	antm	Net Realized Gains Losses On Investments Other Than Temporary Impairment Losses Recognized In Income And Net Change In Net Unrealized Gains Losses On Investments NetRealizedGainsLossesOnInvestmentsOtherThanTemporaryImpairmentLossesRecognizedInIncomeAndNetChangeInNetUnrealizedGainsLossesOnInvestments	-647000000	USD
CY2017	antm	Net Realized Gains Losses On Investments Other Than Temporary Impairment Losses Recognized In Income And Net Change In Net Unrealized Gains Losses On Investments NetRealizedGainsLossesOnInvestmentsOtherThanTemporaryImpairmentLossesRecognizedInIncomeAndNetChangeInNetUnrealizedGainsLossesOnInvestments	340000000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	8351000000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	8380000000	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	9780000000	USD
CY2019Q4	us-gaap	Contractual Obligation ContractualObligation	999000000	USD
CY2018Q4	us-gaap	Contractual Obligation ContractualObligation	873000000	USD

CY2018Q4

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

486000000

USD

CY2019Q4

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

487000000

USD

CY2017

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

35000000

USD

CY2018

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-29000000

USD

CY2019

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

9000000

USD

CY2019

dei

Amendment Flag

AmendmentFlag

false

CY2019

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2019

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

FY

CY2019

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2019

CY2019

dei

Document Period End Date

DocumentPeriodEndDate

2019-12-31

CY2019

dei

Entity Central Index Key

EntityCentralIndexKey

0001156039

CY2018Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

16894000000

USD

CY2019Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

19021000000

USD

CY2018Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2019Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2018Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2019Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2018Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

257395577

shares

CY2019Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

252922161

shares

CY2018Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

257395577

shares

CY2019Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

252922161

shares

CY2017

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

153000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

13000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

-133000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

-1000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

198000000

USD

CY2019

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

46204

CY2019

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

CY2019

dei

City Area Code

CityAreaCode

(800)

CY2019

dei

Local Phone Number

LocalPhoneNumber

331-1476

CY2019

dei

Entity Shell Company

EntityShellCompany

false

CY2019

dei

Security12b Title

Security12bTitle

Common Stock, Par Value $0.01

CY2017

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

-58000000

USD

CY2019

dei

Trading Symbol

TradingSymbol

ANTM

CY2019

dei

Security Exchange Name

SecurityExchangeName

NYSE

CY2019

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

-4000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

99000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-140000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

199000000

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

-35000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

10000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

-4000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities

3000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities

-1000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities

0

USD

CY2018Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2019Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2018Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2019Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2018Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2019Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2018Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2019Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2019

dei

Document Type

DocumentType

10-K

CY2019

dei

Document Annual Report

DocumentAnnualReport

true

CY2019

dei

Document Transition Report

DocumentTransitionReport

false

CY2019

dei

Entity File Number

EntityFileNumber

001-16751

CY2019

dei

Entity Registrant Name

EntityRegistrantName

ANTHEM, INC.

CY2019

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

IN

CY2019

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

35-2145715

CY2019

dei

Entity Address Address Line1

EntityAddressAddressLine1

220 Virginia Avenue

CY2019

dei

Entity Address City Or Town

EntityAddressCityOrTown

Indianapolis

CY2019

dei

Entity Address State Or Province

EntityAddressStateOrProvince

IN

CY2019

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2019

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2019

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2019

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2019

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2019Q4

us-gaap

Assets

77453000000

USD

CY2018Q4

us-gaap

Assets

71571000000

USD

CY2019

dei

Entity Small Business

EntitySmallBusiness

false

CY2018Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

3726000000

USD

CY2019Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3133000000

USD

CY2019

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2019Q2

dei

Entity Public Float

EntityPublicFloat

72160040688

USD

CY2018Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

2735000000

USD

CY2019Q4

us-gaap

Goodwill

20500000000

USD

CY2020Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

252329919

shares

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3934000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

19676000000

USD

CY2018Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

16692000000

USD

CY2019Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

1009000000

USD

CY2018Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

1493000000

USD

CY2019Q4

us-gaap

Other Short Term Investments

OtherShortTermInvestments

13000000

USD

CY2018Q4

us-gaap

Other Short Term Investments

OtherShortTermInvestments

21000000

USD

CY2019Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

173000000

USD

CY2018Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

162000000

USD

CY2019Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5173000000

USD

CY2018Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

4465000000

USD

CY2019Q4

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2411000000

USD

CY2018Q4

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2278000000

USD

CY2019Q4

us-gaap

Other Receivables

OtherReceivables

2634000000

USD

CY2018Q4

us-gaap

Other Receivables

OtherReceivables

2558000000

USD

CY2019Q4

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

335000000

USD

CY2018Q4

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

10000000

USD

CY2019Q4

us-gaap

Securities Received As Collateral

SecuritiesReceivedAsCollateral

353000000

USD

CY2018Q4

us-gaap

Securities Received As Collateral

SecuritiesReceivedAsCollateral

604000000

USD

CY2019Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

2319000000

USD

CY2018Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

2104000000

USD

CY2019Q4

us-gaap

Assets Current

AssetsCurrent

39033000000

USD

CY2018Q4

us-gaap

Assets Current

AssetsCurrent

34321000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

505000000

USD

CY2018Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

487000000

USD

CY2019Q4

antm

Equitysecurities Longterm

EquitysecuritiesLongterm

30000000

USD

CY2018Q4

antm

Equitysecurities Longterm

EquitysecuritiesLongterm

33000000

USD

CY2019Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

4228000000

USD

CY2018Q4

us-gaap

Goodwill

20504000000

USD

CY2019Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

8674000000

USD

CY2018Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9007000000

USD

CY2019Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1350000000

USD

CY2018Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

758000000

USD

CY2019Q4

antm

Liability For Future Policy Benefits Current

LiabilityForFuturePolicyBenefitsCurrent

85000000

USD

CY2019Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2018Q4

antm

Liability For Future Policy Benefits Current

LiabilityForFuturePolicyBenefitsCurrent

75000000

USD

CY2019Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

3050000000

USD

CY2019Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

8842000000

USD

CY2018Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

7454000000

USD

CY2018Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

2590000000

USD

CY2019Q4

us-gaap

Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense

LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense

11977000000

USD

CY2018Q4

us-gaap

Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense

LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense

10119000000

USD

CY2019Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1017000000

USD

CY2018Q4

us-gaap

Unearned Premiums

UnearnedPremiums

902000000

USD

CY2019Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

4198000000

USD

CY2018Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

4959000000

USD

CY2019Q4

srt

Payables To Broker Dealers And Clearing Organizations

PayablesToBrokerDealersAndClearingOrganizations

84000000

USD

CY2018Q4

srt

Payables To Broker Dealers And Clearing Organizations

PayablesToBrokerDealersAndClearingOrganizations

197000000

USD

CY2019Q4

us-gaap

Deposits Received For Securities Loaned At Carrying Value

DepositsReceivedForSecuritiesLoanedAtCarryingValue

351000000

USD

CY2018Q4

us-gaap

Deposits Received For Securities Loaned At Carrying Value

DepositsReceivedForSecuritiesLoanedAtCarryingValue

604000000

USD

CY2019Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

700000000

USD

CY2018Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

1145000000

USD

CY2019Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1598000000

USD

CY2018Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

849000000

USD

CY2019Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

3692000000

USD

CY2018Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

3190000000

USD

CY2019Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

23617000000

USD

CY2018Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

21965000000

USD

CY2019Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17787000000

USD

CY2018Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17217000000

USD

CY2019Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

674000000

USD

CY2018Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

706000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

2227000000

USD

CY2018Q4

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

1960000000

USD

CY2019Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1420000000

USD

CY2018Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1182000000

USD

CY2019Q4

us-gaap

Liabilities

45725000000

USD

CY2018Q4

us-gaap

Liabilities

43030000000

USD

CY2019Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2018Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2018Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2019Q4

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2018Q4

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2019Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9448000000

USD

CY2018Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9536000000

USD

CY2019Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

22573000000

USD

CY2018Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

19988000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-296000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-986000000

USD

CY2019Q4

us-gaap

Stockholders Equity

StockholdersEquity

31728000000

USD

CY2018Q4

us-gaap

Stockholders Equity

StockholdersEquity

28541000000

USD

CY2019Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

77453000000

USD

CY2018Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

71571000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2018

us-gaap

Premiums Earned Net

PremiumsEarnedNet

85421000000

USD

CY2017

us-gaap

Premiums Earned Net

PremiumsEarnedNet

83648000000

USD

CY2019

us-gaap

Other Income

OtherIncome

8968000000

USD

CY2018

us-gaap

Other Income

OtherIncome

5920000000

USD

CY2017

us-gaap

Other Income

OtherIncome

5413000000

USD

CY2019

antm

Operating Revenue

OperatingRevenue

103141000000

USD

CY2018

antm

Operating Revenue

OperatingRevenue

91341000000

USD

CY2017

antm

Operating Revenue

OperatingRevenue

89061000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2018

us-gaap

Net Investment Income

NetInvestmentIncome

970000000

USD

CY2017

us-gaap

Net Investment Income

NetInvestmentIncome

867000000

USD

CY2019

antm

Netrealizedlossesgainsonfinancialinstruments

114000000

USD

CY2018

antm

Netrealizedlossesgainsonfinancialinstruments

-180000000

USD

CY2017

antm

Netrealizedlossesgainsonfinancialinstruments

145000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

53000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

29000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

35000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

-6000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

-3000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

-2000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

47000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

26000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

33000000

USD

CY2019

us-gaap

Revenues

104213000000

USD

CY2018

us-gaap

Revenues

92105000000

USD

CY2017

us-gaap

Revenues

90040000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2018

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

71895000000

USD

CY2017

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

72236000000

USD

CY2019

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

1992000000

USD

CY2018

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

0

USD

CY2017

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

0

USD

CY2019

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

13364000000

USD

CY2018

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

14020000000

USD

CY2017

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

12650000000

USD

CY2019

us-gaap

Interest Expense

InterestExpense

746000000

USD

CY2018

us-gaap

Interest Expense

InterestExpense

753000000

USD

CY2017

us-gaap

Interest Expense

InterestExpense

739000000

USD

CY2019

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

338000000

USD

CY2018

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

358000000

USD

CY2017

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

169000000

USD

CY2019

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-2000000

USD

CY2018

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-11000000

USD

CY2017

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-282000000

USD

CY2019

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

98228000000

USD

CY2018

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

87037000000

USD

CY2017

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

86076000000

USD

CY2019

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5985000000

USD

CY2018

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5068000000

USD

CY2017

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

3964000000

USD

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2018

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1318000000

USD

CY2017

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

121000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2018

us-gaap

Net Income Loss

NetIncomeLoss

3750000000

USD

CY2017

us-gaap

Net Income Loss

NetIncomeLoss

3843000000

USD

CY2019

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

18.81

CY2018

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

14.53

CY2017

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

14.70

CY2019

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

18.47

CY2018

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

14.19

CY2017

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

14.35

CY2019

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.20

CY2018

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.00

CY2017

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

2.70

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2018

us-gaap

Net Income Loss

NetIncomeLoss

3750000000

USD

CY2017

us-gaap

Net Income Loss

NetIncomeLoss

3843000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

680000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

-418000000

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

173000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities

0

USD

CY2019

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

81000000

USD

CY2018

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

91000000

USD

CY2017

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-1272000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities

2000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities

-4000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

-16000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

37000000

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

-65000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-26000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

90000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-51000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

CY2018

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-1000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

3000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-474000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

166000000

USD

CY2019

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

5497000000

USD

CY2018

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

3276000000

USD

CY2017

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

4009000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2018

us-gaap

Net Income Loss

NetIncomeLoss

3750000000

USD

CY2017

us-gaap

Net Income Loss

NetIncomeLoss

3843000000

USD

CY2019

antm

Netrealizedlossesgainsonfinancialinstruments

114000000

USD

CY2018

antm

Netrealizedlossesgainsonfinancialinstruments

-180000000

USD

CY2017

antm

Netrealizedlossesgainsonfinancialinstruments

145000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

47000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

26000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

33000000

USD

CY2019

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-2000000

USD

CY2018

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-11000000

USD

CY2017

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-282000000

USD

CY2019

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

-3000000

USD

CY2018

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

-13000000

USD

CY2017

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

-15000000

USD

CY2019

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

986000000

USD

CY2018

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

1008000000

USD

CY2017

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

780000000

USD

CY2019

us-gaap

Depreciation

147000000

USD

CY2018

us-gaap

Depreciation

124000000

USD

CY2017

us-gaap

Depreciation

111000000

USD

CY2017

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

22000000

USD

CY2019

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

48000000

USD

CY2019

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

1053000000

USD

CY2018

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

695000000

USD

CY2018

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

6442000000

USD

CY2017

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

7932000000

USD

CY2019

us-gaap

Share Based Compensation

ShareBasedCompensation

294000000

USD

CY2018

us-gaap

Share Based Compensation

ShareBasedCompensation

226000000

USD

CY2017

us-gaap

Share Based Compensation

ShareBasedCompensation

170000000

USD

CY2018

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

1000000

USD

CY2017

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

36000000

USD

CY2019

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

170000000

USD

CY2018

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

26000000

USD

CY2017

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

629000000

USD

CY2019

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

1826000000

USD

CY2018

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

-1059000000

USD

CY2017

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

732000000

USD

CY2019

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

115000000

USD

CY2018

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

-36000000

USD

CY2017

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

-120000000

USD

CY2019

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-593000000

USD

CY2018

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

122000000

USD

CY2017

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

922000000

USD

CY2019

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

148000000

USD

CY2018

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

-25000000

USD

CY2017

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

-120000000

USD

CY2019

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

-325000000

USD

CY2018

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

323000000

USD

CY2017

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

-194000000

USD

CY2019

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

92000000

USD

CY2018

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

205000000

USD

CY2017

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

165000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

6061000000

USD

CY2018

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

3827000000

USD

CY2017

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

4185000000

USD

CY2019

us-gaap

Payments To Acquire Available For Sale Securities Debt

PaymentsToAcquireAvailableForSaleSecuritiesDebt

10487000000

USD

CY2018

us-gaap

Payments To Acquire Available For Sale Securities Debt

PaymentsToAcquireAvailableForSaleSecuritiesDebt

8244000000

USD

CY2017

us-gaap

Payments To Acquire Available For Sale Securities Debt

PaymentsToAcquireAvailableForSaleSecuritiesDebt

9795000000

USD

CY2019

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

5914000000

USD

CY2019

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

2437000000

USD

CY2018

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

1938000000

USD

CY2017

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

1848000000

USD

CY2019

antm

Paymentstoacquireequitysecurities

11825000000

USD

CY2018

antm

Paymentstoacquireequitysecurities

896000000

USD

CY2017

antm

Paymentstoacquireequitysecurities

5416000000

USD

CY2019

antm

Proceedsfromsaleofequitysecurities

12364000000

USD

CY2018

antm

Proceedsfromsaleofequitysecurities

2809000000

USD

CY2017

antm

Proceedsfromsaleofequitysecurities

3463000000

USD

CY2019

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

642000000

USD

CY2018

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

531000000

USD

CY2017

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

1164000000

USD

CY2019

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

320000000

USD

CY2018

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

411000000

USD

CY2017

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

219000000

USD

CY2019

us-gaap

Payments For Proceeds From Derivative Instrument Investing Activities

PaymentsForProceedsFromDerivativeInstrumentInvestingActivities

0

USD

CY2018

us-gaap

Payments For Proceeds From Derivative Instrument Investing Activities

PaymentsForProceedsFromDerivativeInstrumentInvestingActivities

0

USD

CY2017

us-gaap

Payments For Proceeds From Derivative Instrument Investing Activities

PaymentsForProceedsFromDerivativeInstrumentInvestingActivities

-65000000

USD

CY2019

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

-254000000

USD

CY2018

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

149000000

USD

CY2017

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

-625000000

USD

CY2019

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

USD

CY2018

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1760000000

USD

CY2017

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

2080000000

USD

CY2019

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1077000000

USD

CY2018

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1208000000

USD

CY2017

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

791000000

USD

CY2019

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

50000000

USD

CY2018

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

71000000

USD

CY2017

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-12000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-2792000000

USD

CY2018

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-1259000000

USD

CY2017

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-5082000000

USD

CY2019

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-297000000

USD

CY2018

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-107000000

USD

CY2017

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

175000000

USD

CY2019

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2473000000

USD

CY2018

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

835000000

USD

CY2017

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

5458000000

USD

CY2019

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1123000000

USD

CY2018

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1684000000

USD

CY2017

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

2815000000

USD

CY2019

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

7590000000

USD

CY2018

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

9120000000

USD

CY2017

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

5835000000

USD

CY2019

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

8035000000

USD

CY2018

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

9250000000

USD

CY2017

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

5000000000

USD

CY2019

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-254000000

USD

CY2018

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

150000000

USD

CY2017

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-625000000

USD

CY2019

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-169000000

USD

CY2018

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-210000000

USD

CY2017

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

71000000

USD

CY2019

us-gaap

Payments For Hedge Financing Activities

PaymentsForHedgeFinancingActivities

1000000

USD

CY2018

us-gaap

Payments For Hedge Financing Activities

PaymentsForHedgeFinancingActivities

0

USD

CY2017Q1

us-gaap

Payments For Hedge Financing Activities

PaymentsForHedgeFinancingActivities

0

USD

CY2019

us-gaap

Proceeds From Hedge Financing Activities

ProceedsFromHedgeFinancingActivities

0

USD

CY2018

us-gaap

Proceeds From Hedge Financing Activities

ProceedsFromHedgeFinancingActivities

1000000

USD

CY2017

us-gaap

Proceeds From Hedge Financing Activities

ProceedsFromHedgeFinancingActivities

1000000

USD

CY2019

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

0

USD

CY2018

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

1250000000

USD

CY2017

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

0

USD

CY2019

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1701000000

USD

CY2018

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1685000000

USD

CY2017

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1998000000

USD

CY2019

antm

Payments For Proceeds From Financing Derivatives

PaymentsForProceedsFromFinancingDerivatives

34000000

USD

CY2018

antm

Payments For Proceeds From Financing Derivatives

PaymentsForProceedsFromFinancingDerivatives

-23000000

USD

CY2017

antm

Payments For Proceeds From Financing Derivatives

PaymentsForProceedsFromFinancingDerivatives

149000000

USD

CY2019

us-gaap

Payments Of Dividends

PaymentsOfDividends

818000000

USD

CY2018

us-gaap

Payments Of Dividends

PaymentsOfDividends

776000000

USD

CY2017

us-gaap

Payments Of Dividends

PaymentsOfDividends

705000000

USD

CY2019

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

187000000

USD

CY2018

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

173000000

USD

CY2017

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

225000000

USD

CY2019

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

84000000

USD

CY2018

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

81000000

USD

CY2017

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

46000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-2266000000

USD

CY2018

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-2241000000

USD

CY2017

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

427000000

USD

CY2019

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

0

USD

CY2018

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

-2000000

USD

CY2017

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

4000000

USD

CY2019

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

1003000000

USD

CY2018

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

325000000

USD

CY2017

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

-466000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3934000000

USD

CY2017Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3609000000

USD

CY2016Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4075000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3934000000

USD

CY2017Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3609000000

USD

CY2016Q4

us-gaap

Stockholders Equity

StockholdersEquity

25101000000

USD

CY2017

us-gaap

Net Income Loss

NetIncomeLoss

3843000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

166000000

USD

CY2017

antm

Net Adjustment To Additional Paid In Capital For Equity Hedge

NetAdjustmentToAdditionalPaidInCapitalForEquityHedge

1000000

USD

CY2017

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1998000000

USD

CY2017

us-gaap

Dividends Common Stock

DividendsCommonStock

707000000

USD

CY2017

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

342000000

USD

CY2017

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-245000000

USD

CY2017Q4

us-gaap

Stockholders Equity

StockholdersEquity

26503000000

USD

CY2017Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1

26503000000

USD

CY2018

us-gaap

Net Income Loss

NetIncomeLoss

3750000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-474000000

USD

CY2018

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

1250000000

USD

CY2018

antm

Net Adjustment To Additional Paid In Capital For Equity Hedge

NetAdjustmentToAdditionalPaidInCapitalForEquityHedge

1000000

USD

CY2018

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1685000000

USD

CY2018

us-gaap

Dividends Common Stock

DividendsCommonStock

785000000

USD

CY2018

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

318000000

USD

CY2018

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-337000000

USD

CY2018Q4

us-gaap

Stockholders Equity

StockholdersEquity

28541000000

USD

CY2018Q4

us-gaap

Cumulative Effect Of New Accounting Principle In Period Of Adoption

CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

26000000

USD

CY2018Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1

28567000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

690000000

USD

CY2019

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1701000000

USD

CY2019

us-gaap

Dividends Common Stock

DividendsCommonStock

822000000

USD

CY2019

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

396000000

USD

CY2019

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-209000000

USD

CY2019Q4

us-gaap

Stockholders Equity

StockholdersEquity

31728000000

USD

CY2019

us-gaap

Nature Of Operations

NatureOfOperations

Organization<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. </span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately </span><span style="font-family:inherit;font-size:10pt;"><span>41</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">medical members through our affiliated health plans as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs;</span><span style="font-family:inherit;font-size:10pt;"> Health Maintenance Organizations, or HMOs; Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as pharmacy benefits management, or PBM, dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits, or FEHB, Program. </span></div><span style="font-family:inherit;font-size:10pt;">We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York)</span><span style="font-family:inherit;font-size:10pt;">, Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states across the country as Aim Specialty Health, Amerigroup, Aspire Health, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or UniCare. Also, in the second quarter of 2019, we began providing PBM services through our IngenioRx subsidiary.</span><span style="font-family:inherit;font-size:10pt;"> We are licensed to conduct insurance operations in all </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>50</span></span><span style="font-family:inherit;font-size:10pt;"> states and the District of Columbia through our subsidiaries.</span>

CY2019Q4

antm

Number Of Medical Members

NumberOfMedicalMembers

41000000

medical_member

CY2019Q4

antm

Number Of Counties In Geographical Region Not Served

NumberOfCountiesInGeographicalRegionNotServed

30

counties

CY2019Q4

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

states

CY2019

us-gaap

Prior Period Reclassification Adjustment Description

PriorPeriodReclassificationAdjustmentDescription

<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications:</span><span style="font-family:inherit;font-size:10pt;"> Certain prior year amounts have been reclassified to conform to the current year presentation.</span></div>

CY2019

us-gaap

Use Of Estimates

UseOfEstimates

<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates:</span><span style="font-family:inherit;font-size:10pt;"> The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>

CY2019Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

215000000

USD

CY2018Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

222000000

USD

CY2019

antm

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2019Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

237000000

USD

CY2019Q4

antm

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

46000000

USD

CY2018Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

278000000

USD

CY2018Q4

antm

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

47000000

USD

CY2019Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

242000000

USD

CY2018Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

280000000

USD

CY2019

us-gaap

Defined Benefit Plan Alternative Method Used To Amortize Net Gains And Losses

DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses

We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.

CY2018Q4

antm

Patient Protection Affordable Care Act Health Insurance Provider Fee

PatientProtectionAffordableCareActHealthInsuranceProviderFee

14300000000

USD

CY2018

antm

Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid

PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid

1544000000

USD

CY2019

antm

Reserves For Future Policy Benefits Maximum Payable Period

ReservesForFuturePolicyBenefitsMaximumPayablePeriod

P1Y

CY2019

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent

SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

0.90

CY2019

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

467000000

USD

CY2018

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

385000000

USD

CY2017

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

338000000

USD

CY2018Q1

us-gaap

New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1

NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1

91000000

USD

CY2017

us-gaap

New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Net Income

NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome

36000000

USD

CY2017

antm

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Per Share Amount

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPerShareAmount

0.13

CY2018Q1

us-gaap

Cumulative Effect Of New Accounting Principle In Period Of Adoption

CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

320000000

USD

CY2019

us-gaap

Description Of New Accounting Pronouncements Not Yet Adopted

DescriptionOfNewAccountingPronouncementsNotYetAdopted

<div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted: </span><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,</span><span style="font-family:inherit;font-size:10pt;"> or ASU 2019-12. The amendments in ASU 2019-12 remove certain exceptions to the general principles in ASC Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We are currently evaluating the effects the adoption of ASU 2019-12 will have on our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2019, the FASB issued Accounting Standards Update No. 2019-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="font-family:inherit;font-size:10pt;">. In May 2019, the FASB issued Accounting Standards Update No. 2019-05, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief</span><span style="font-family:inherit;font-size:10pt;">. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">. In November 2018, the FASB issued Accounting Standards Update No. 2018-19, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="font-family:inherit;font-size:10pt;">. These updates provide an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost and provide additional clarification and implementation guidance on certain aspects of the previously issued Accounting Standards Update No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="font-family:inherit;font-size:10pt;"> or ASU 2016-13, and have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 introduces a current expected credit loss model for measuring expected credit losses for certain types of financial instruments </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">held at the reporting date based on historical experience, current conditions and reasonable supportable forecasts. ASU 2016-13 replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities and provides for additional disclosure requirements. ASU 2016-13 requires a cumulative-effect adjustment to the opening balance of retained earnings on the statement of financial position at the date of adoption and a prospective transition approach for debt securities for which an OTTI had been recognized before the adoption date. The effect of a prospective transition approach is to maintain the same amortized cost basis before and after the date of adoption. We adopted ASU 2016-13 on January 1, 2020, and the adoption did not have a material impact on our beginning retained earnings or on our consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2018-15. The amendments in ASU 2018-15 require implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The amendments also require an entity to disclose the nature of its hosting arrangements and adhere to certain presentation requirements in its balance sheet, income statement and statement of cash flows. We adopted ASU 2018-15 on January 1, 2020 using a prospective approach for all implementation costs incurred after the date of adoption, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Retirement Benefits—Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2018-14. The amendments in ASU 2018-14 eliminate, add and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective basis to all periods presented. We are currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Services Insurance (Topic</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">944): Targeted Improvements to the Accounting for Long-Duration Contracts, </span><span style="font-family:inherit;font-size:10pt;">or ASU 2018-12. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments in ASU 2018-12 will be effective for our interim and annual reporting periods beginning after December 15, 2021. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued Accounting Standards Update No. 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2017-04. This update removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. Upon adoption, the guidance is to be applied prospectively. We adopted ASU 2017-04 on January 1, 2020, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no other new accounting pronouncements that were issued or became effective during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> that had, or are expected to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.</span></div>

CY2019Q4

antm

Merger Agreement Termination Fee

MergerAgreementTerminationFee

1850000000

USD

CY2019Q4

antm

Equity Securities

EquitySecurities

1039000000

USD

CY2018Q4

antm

Equity Securities

EquitySecurities

1526000000

USD

CY2019

us-gaap

Investment Income Net

InvestmentIncomeNet

1034000000

USD

CY2018

us-gaap

Investment Income Net

InvestmentIncomeNet

1011000000

USD

CY2017

us-gaap

Investment Income Net

InvestmentIncomeNet

908000000

USD

CY2019

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

29000000

USD

CY2018

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

41000000

USD

CY2017

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

41000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2018

us-gaap

Net Investment Income

NetInvestmentIncome

970000000

USD

CY2017

us-gaap

Net Investment Income

NetInvestmentIncome

867000000

USD

CY2019

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

131000000

USD

CY2018

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

-203000000

USD

CY2017

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

200000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

47000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

26000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

33000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

874000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

-524000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

257000000

USD

CY2019

antm

Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments

DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments

194000000

USD

CY2018

antm

Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments

DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments

-106000000

USD

CY2017

antm

Deferred Income Tax Expense Benefit Related To Unrealized Gain Loss On Investments

DeferredIncomeTaxExpenseBenefitRelatedToUnrealizedGainLossOnInvestments

84000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

680000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

-418000000

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

173000000

USD

CY2019

antm

Net Realized Gains Losses On Investments Other Than Temporary Impairment Losses Recognized In Income And Net Change In Net Unrealized Gains Losses On Investments

NetRealizedGainsLossesOnInvestmentsOtherThanTemporaryImpairmentLossesRecognizedInIncomeAndNetChangeInNetUnrealizedGainsLossesOnInvestments

764000000

USD

CY2018

antm

Net Realized Gains Losses On Investments Other Than Temporary Impairment Losses Recognized In Income And Net Change In Net Unrealized Gains Losses On Investments

NetRealizedGainsLossesOnInvestmentsOtherThanTemporaryImpairmentLossesRecognizedInIncomeAndNetChangeInNetUnrealizedGainsLossesOnInvestments

-647000000

USD

CY2017

antm

Net Realized Gains Losses On Investments Other Than Temporary Impairment Losses Recognized In Income And Net Change In Net Unrealized Gains Losses On Investments

NetRealizedGainsLossesOnInvestmentsOtherThanTemporaryImpairmentLossesRecognizedInIncomeAndNetChangeInNetUnrealizedGainsLossesOnInvestments

340000000

USD

CY2019

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

8351000000

USD

CY2018

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

8380000000

USD

CY2017

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

9780000000

USD

CY2019Q4

us-gaap

Contractual Obligation

ContractualObligation

999000000

USD

CY2018Q4

us-gaap

Contractual Obligation

ContractualObligation

873000000

USD

CY2019Q4

us-gaap

Assets Held By Insurance Regulators

AssetsHeldByInsuranceRegulators

505000000

USD

CY2018Q4

us-gaap

Assets Held By Insurance Regulators

AssetsHeldByInsuranceRegulators

487000000

USD

CY2019Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

351000000

USD

CY2018Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

604000000

USD

CY2019

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.03

CY2018

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2019Q4

us-gaap

Derivative Asset Collateral Obligation To Return Cash Offset

DerivativeAssetCollateralObligationToReturnCashOffset

22000000

USD

CY2018Q4

us-gaap

Derivative Liability Collateral Right To Reclaim Cash Offset

DerivativeLiabilityCollateralRightToReclaimCashOffset

1000000

USD

CY2019Q4

us-gaap

Derivative Notional Amount

DerivativeNotionalAmount

1335000000

USD

CY2019Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

23000000

USD

CY2019Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

1000000

USD

CY2019Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

1000000

USD

CY2019Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

1000000

USD

CY2019Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

22000000

USD

CY2019Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

0

USD

CY2018Q4

us-gaap

Derivative Notional Amount

DerivativeNotionalAmount

1879000000

USD

CY2018Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

16000000

USD

CY2018Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

17000000

USD

CY2018Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

14000000

USD

CY2018Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

14000000

USD

CY2018Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

2000000

USD

CY2018Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

3000000

USD

CY2019

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-17000000

USD

CY2018

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

23000000

USD

CY2017

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-48000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2015000000

USD

CY2019Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

353000000

USD

CY2019Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

23624000000

USD

CY2019Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

1000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

1815000000

USD

CY2018Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

604000000

USD

CY2018Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

21161000000

USD

CY2018Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

17000000

USD

CY2018Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

623000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-13000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

3000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

189000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

101000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

79000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

5000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

230000000

USD

CY2019Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

397000000

USD

CY2019

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

6000000

USD

CY2017Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

537000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-228000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-5000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

430000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

69000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

99000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

74000000

USD

CY2017

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-3000000

USD

CY2018

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

17000000

USD

CY2018Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

623000000

USD

CY2018

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

30000000

USD

CY2016Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

481000000

USD

CY2017

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-1000000

USD

CY2017

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

14000000

USD

CY2017

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

217000000

USD

CY2017

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

55000000

USD

CY2017

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

73000000

USD

CY2017

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

33000000

USD

CY2017

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

79000000

USD

CY2017Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

537000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

211000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

226000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

280000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

301000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

114000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

96000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

4000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

7000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

82000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

104000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets State Taxes

DeferredTaxAssetsStateTaxes

11000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets State Taxes

DeferredTaxAssetsStateTaxes

32000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

22000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

20000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Other Comprehensive Loss

DeferredTaxAssetsOtherComprehensiveLoss

0

USD

CY2018Q4

us-gaap

Deferred Tax Assets Other Comprehensive Loss

DeferredTaxAssetsOtherComprehensiveLoss

41000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

77000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

72000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

801000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

899000000

USD

CY2019Q4

antm

Deferred Tax Liabilities Investment Basis

DeferredTaxLiabilitiesInvestmentBasis

78000000

USD

CY2018Q4

antm

Deferred Tax Liabilities Investment Basis

DeferredTaxLiabilitiesInvestmentBasis

52000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Other Comprehensive Income

DeferredTaxLiabilitiesOtherComprehensiveIncome

153000000

USD

CY2018Q4

us-gaap

Deferred Tax Liabilities Other Comprehensive Income

DeferredTaxLiabilitiesOtherComprehensiveIncome

0

USD

CY2019Q4

antm

Deferred Tax Liabilities Trademarks State Medicaid Licenses

DeferredTaxLiabilitiesTrademarksStateMedicaidLicenses

1529000000

USD

CY2018Q4

antm

Deferred Tax Liabilities Trademarks State Medicaid Licenses

DeferredTaxLiabilitiesTrademarksStateMedicaidLicenses

1529000000

USD

CY2019Q4

antm

Deferred Tax Liabilities Relating To Customer Provider Hospital Relationships

DeferredTaxLiabilitiesRelatingToCustomerProviderHospitalRelationships

239000000

USD

CY2018Q4

antm

Deferred Tax Liabilities Relating To Customer Provider Hospital Relationships

DeferredTaxLiabilitiesRelatingToCustomerProviderHospitalRelationships

290000000

USD

CY2019Q4

antm

Deferred Tax Liabilities Relating To Capitalized Software Other

DeferredTaxLiabilitiesRelatingToCapitalizedSoftwareOther

528000000

USD

CY2018Q4

antm

Deferred Tax Liabilities Relating To Capitalized Software Other

DeferredTaxLiabilitiesRelatingToCapitalizedSoftwareOther

461000000

USD

CY2019Q4

antm

Deferred Taxliabilities Deferred Expense Retirementbenefits

DeferredTaxliabilitiesDeferredExpenseRetirementbenefits

194000000

USD

CY2018Q4

antm

Deferred Taxliabilities Deferred Expense Retirementbenefits

DeferredTaxliabilitiesDeferredExpenseRetirementbenefits

183000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Deferred Expense Deferred Financing Costs

DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts

19000000

USD

CY2018Q4

us-gaap

Deferred Tax Liabilities Deferred Expense Deferred Financing Costs

DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts

27000000

USD

CY2019Q4

antm

Deferred Tax Liabilities Relating To State Deferred Tax

DeferredTaxLiabilitiesRelatingToStateDeferredTax

77000000

USD

CY2018Q4

antm

Deferred Tax Liabilities Relating To State Deferred Tax

DeferredTaxLiabilitiesRelatingToStateDeferredTax

105000000

USD

CY2019Q4

antm

Deferred Tax Assets Related To Depreciation And Amortization

DeferredTaxAssetsRelatedToDepreciationAndAmortization

48000000

USD

CY2018Q4

antm

Deferred Tax Assets Related To Depreciation And Amortization

DeferredTaxAssetsRelatedToDepreciationAndAmortization

47000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Other

DeferredTaxLiabilitiesOther

163000000

USD

CY2018Q4

us-gaap

Deferred Tax Liabilities Other

DeferredTaxLiabilitiesOther

165000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Gross Noncurrent

DeferredTaxLiabilitiesGrossNoncurrent

3028000000

USD

CY2018Q4

us-gaap

Deferred Tax Liabilities Gross Noncurrent

DeferredTaxLiabilitiesGrossNoncurrent

2859000000

USD

CY2019Q4

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

2227000000

USD

CY2018Q4

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

1960000000

USD

CY2019Q4

us-gaap

Operating Loss Carryforwards Valuation Allowance

OperatingLossCarryforwardsValuationAllowance

45000000

USD

CY2018Q4

us-gaap

Operating Loss Carryforwards Valuation Allowance

OperatingLossCarryforwardsValuationAllowance

95000000

USD

CY2019

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1019000000

USD

CY2018

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1128000000

USD

CY2017

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1356000000

USD

CY2019

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

84000000

USD

CY2018

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

78000000

USD

CY2017

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

39000000

USD

CY2019

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1103000000

USD

CY2018

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1206000000

USD

CY2017

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1395000000

USD

CY2019

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

75000000

USD

CY2017

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1387000000

USD

CY2017

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.350

CY2019

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

138000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.023

CY2018

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

63000000

USD

CY2018

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

112000000

USD

CY2017

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

-1274000000

USD

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2018

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1318000000

USD

CY2017

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

121000000

USD

CY2019

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1257000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2018

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1064000000

USD

CY2018

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2018

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.012

CY2017

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

-2000000

USD

CY2017

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

-0.001

CY2019

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

24000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.004

CY2018

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

27000000

USD

CY2018

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.005

CY2017

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

58000000

USD

CY2017

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.014

CY2019

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

0

USD

CY2019

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0

CY2018

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

324000000

USD

CY2018

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0.064

CY2017

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

0

USD

CY2017

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0

CY2019

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

0

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate

EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate

0

CY2018

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

-28000000

USD

CY2018

us-gaap

Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate

EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate

-0.006

CY2017

us-gaap

Income Tax Reconciliation Change In Enacted Tax Rate

IncomeTaxReconciliationChangeInEnactedTaxRate

-1108000000

USD

CY2017

us-gaap

Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate

EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate

-0.279

CY2019

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-193000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.032

CY2018

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-78000000

USD

CY2018

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.015

CY2017

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-98000000

USD

CY2017

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.025

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2019

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.197

CY2018

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1318000000

USD

CY2018

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.260

CY2017

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

121000000

USD

CY2017

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.031

CY2018

antm

Reclassificationofstrandedtaxeffectsresultingfromthe Tax Cutsand Jobs Act

ReclassificationofstrandedtaxeffectsresultingfromtheTaxCutsandJobsAct

91000000

USD

CY2018Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

241000000

USD

CY2017Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

190000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

1000000

USD

CY2018

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

35000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

0

USD

CY2018

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

50000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

63000000

USD

CY2018

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

31000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities

UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

33000000

USD

CY2018

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities

UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

3000000

USD

CY2019Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

146000000

USD

CY2018Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

241000000

USD

CY2019Q4

us-gaap

Unrecognized Tax Benefits That Would Impact Effective Tax Rate

UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

140000000

USD

CY2018Q4

us-gaap

Unrecognized Tax Benefits That Would Impact Effective Tax Rate

UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

237000000

USD

CY2019Q4

antm

Unrecognized Tax Benefits That Would Impact Additional Paid In Capital

UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital

2000000

USD

CY2017

antm

Income Tax Refund Claims Filed

IncomeTaxRefundClaimsFiled

310000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-11000000

USD

CY2018

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

15000000

USD

CY2017

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

3000000

USD

CY2019Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

26000000

USD

CY2018Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

37000000

USD

CY2019Q4

us-gaap

Increase In Unrecognized Tax Benefits Is Reasonably Possible

IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

9000000

USD

CY2019Q4

us-gaap

Decrease In Unrecognized Tax Benefits Is Reasonably Possible

DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

102000000

USD

CY2019Q4

us-gaap

Operating Loss Carryforwards

OperatingLossCarryforwards

8000000

USD

CY2019

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1403000000

USD

CY2018

us-gaap

Income Taxes Paid

IncomeTaxesPaid

738000000

USD

CY2018

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

300000

shares

CY2017

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1503000000

USD

CY2019Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

6479000000

USD

CY2018Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

5548000000

USD

CY2019Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

3346000000

USD

CY2018Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

2813000000

USD

CY2019Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3133000000

USD

CY2018Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

2735000000

USD

CY2019

us-gaap

Depreciation

147000000

USD

CY2018

us-gaap

Depreciation

124000000

USD

CY2017

us-gaap

Depreciation

111000000

USD

CY2019

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

528000000

USD

CY2018

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

528000000

USD

CY2017

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

490000000

USD

CY2019

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

450000000

USD

CY2018

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

465000000

USD

CY2017

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

435000000

USD

CY2019Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

3939000000

USD

CY2018Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

3226000000

USD

CY2017Q4

us-gaap

Goodwill

19231000000

USD

CY2018

us-gaap

Goodwill Acquired During Period

GoodwillAcquiredDuringPeriod

1285000000

USD

CY2018

us-gaap

Goodwill Period Increase Decrease

GoodwillPeriodIncreaseDecrease

-12000000

USD

CY2018Q4

us-gaap

Goodwill

20504000000

USD

CY2019

us-gaap

Goodwill Period Increase Decrease

GoodwillPeriodIncreaseDecrease

-4000000

USD

CY2019Q4

us-gaap

Goodwill

20500000000

USD

CY2019Q4

us-gaap

Goodwill Impaired Accumulated Impairment Loss

GoodwillImpairedAccumulatedImpairmentLoss

41000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Gross

FiniteLivedIntangibleAssetsGross

5080000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

3696000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

1384000000

USD

CY2018Q4

us-gaap

Finite Lived Intangible Assets Gross

FiniteLivedIntangibleAssetsGross

5075000000

USD

CY2018Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

3358000000

USD

CY2018Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

1717000000

USD

CY2019Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7290000000

USD

CY2019Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7290000000

USD

CY2018Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7290000000

USD

CY2018Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7290000000

USD

CY2019Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

12370000000

USD

CY2019Q4

antm

Intangible Assets Accumulated Amortization Excluding Goodwill

IntangibleAssetsAccumulatedAmortizationExcludingGoodwill

3696000000

USD

CY2019Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

8674000000

USD

CY2018Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

12365000000

USD

CY2018Q4

antm

Intangible Assets Accumulated Amortization Excluding Goodwill

IntangibleAssetsAccumulatedAmortizationExcludingGoodwill

3358000000

USD

CY2018Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9007000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

290000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

244000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

195000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

162000000

USD

CY2019Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

85000000

USD

CY2019

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-9000000

USD

CY2018

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-5000000

USD

CY2017

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-7000000

USD

CY2019Q4

antm

Defined Benefit Fair Value Due From Brokers

DefinedBenefitFairValueDueFromBrokers

64000000

USD

CY2018Q4

antm

Defined Benefit Fair Value Due From Brokers

DefinedBenefitFairValueDueFromBrokers

69000000

USD

CY2019

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

201000000

USD

CY2018

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

211000000

USD

CY2017

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

142000000

USD

CY2018

us-gaap

Defined Contribution Plan Increase Decrease Cost

DefinedContributionPlanIncreaseDecreaseCost

58000000

USD

CY2019

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 19, “Segment Information”), for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,656</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years redundancies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(190</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,752</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net payments attributable to:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,026</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,294</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,242</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,519</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,303</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,510</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,813</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,025</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,589</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,039</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business combinations and purchase adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,094</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,487</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,581</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years redundancies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(474</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,638</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net payments attributable to:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,748</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,367</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,247</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,409</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(521</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(539</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,726</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business combinations and purchase adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,467</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years redundancies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(671</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net payments attributable to:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,923</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,629</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,805</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,302</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,431</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>

CY2018Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7266000000

USD

CY2018Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2018Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7232000000

USD

CY2019

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

78695000000

USD

CY2019

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

500000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

78195000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

70294000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

6519000000

USD

CY2019

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

76813000000

USD

CY2019Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

8614000000

USD

CY2019Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

33000000

USD

CY2019Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8647000000

USD

CY2017Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7814000000

USD

CY2017Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

105000000

USD

CY2017Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7709000000

USD

CY2018Q4

antm

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

199000000

USD

CY2018

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

69581000000

USD

CY2018

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

930000000

USD

CY2018

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

68651000000

USD

CY2018

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

62748000000

USD

CY2018

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

6579000000

USD

CY2018

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

69327000000

USD

CY2018Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7232000000

USD

CY2018Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2018Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7266000000

USD

CY2016Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7656000000

USD

CY2016Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

539000000

USD

CY2016Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7117000000

USD

CY2017Q4

antm

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

76000000

USD

CY2017

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

70377000000

USD

CY2017

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

1133000000

USD

CY2017

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

69244000000

USD

CY2017

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

62923000000

USD

CY2017

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

5805000000

USD

CY2017

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

68728000000

USD

CY2017Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7709000000

USD

CY2017Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

105000000

USD

CY2017Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7814000000

USD

CY2019

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

500000000

USD

CY2019

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

500000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

325000000

USD

CY2018

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

515000000

USD

CY2017

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

631000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

175000000

USD

CY2018

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

415000000

USD

CY2017

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

502000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

500000000

USD

CY2018

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

930000000

USD

CY2017

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

1133000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

78195000000

USD

CY2018

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

68651000000

USD

CY2017

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

69244000000

USD

CY2019

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3591000000

USD

CY2018

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3244000000

USD

CY2017

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

2992000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2018

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

71895000000

USD

CY2017

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

72236000000

USD

CY2019Q4

us-gaap

Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net

ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet

223482000000

USD

CY2019Q4

us-gaap

Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net

ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet

214868000000

USD

CY2019Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

8614000000

USD

CY2019Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

33000000

USD

CY2019Q4

us-gaap

Shortduration Insurance Contracts Liability For Unpaid Claims And Claim Adjustment Expense Other Reconciling Item

ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem

195000000

USD

CY2019Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

8842000000

USD

CY2019Q4

us-gaap

Long Term Debt

LongTermDebt

19385000000

USD

CY2018Q4

us-gaap

Long Term Debt

LongTermDebt

18066000000

USD

CY2019Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1598000000

USD

CY2018Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

849000000

USD

CY2019Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17787000000

USD

CY2019Q4

us-gaap

Convertible Debt Noncurrent

ConvertibleDebtNoncurrent

145000000

USD

CY2019Q4

us-gaap

Debt Instrument Convertible Carrying Amount Of The Equity Component

DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent

78000000

USD

CY2019

us-gaap

Debt Instrument Convertible Conversion Ratio1

DebtInstrumentConvertibleConversionRatio1

13.9500

CY2019Q4

us-gaap

Debt Instrument Convertible Conversion Price1

DebtInstrumentConvertibleConversionPrice1

71.6843

CY2018Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17217000000

USD

CY2019Q4

us-gaap

Debt Instrument Face Amount

DebtInstrumentFaceAmount

215000000

USD

CY2019Q4

us-gaap

Debt Instrument Unamortized Discount

DebtInstrumentUnamortizedDiscount

68000000

USD

CY2019

us-gaap

Interest Paid

InterestPaid

755000000

USD

CY2018

us-gaap

Interest Paid

InterestPaid

728000000

USD

CY2017

us-gaap

Interest Paid

InterestPaid

778000000

USD

CY2019Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

1998000000

USD

CY2019Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

699000000

USD

CY2019Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

1594000000

USD

CY2019Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Four

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

1013000000

USD

CY2019Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

1641000000

USD

CY2019Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal After Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

12440000000

USD

CY2019Q4

antm

Gross Premium Tax Rate

GrossPremiumTaxRate

0.0235

CY2019Q4

antm

Merger Agreement Termination Fee

MergerAgreementTerminationFee

1850000000

USD

CY2019

us-gaap

Share Based Compensation

ShareBasedCompensation

294000000

USD

CY2018

us-gaap

Share Based Compensation

ShareBasedCompensation

226000000

USD

CY2017

us-gaap

Share Based Compensation

ShareBasedCompensation

170000000

USD

CY2019

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

78000000

USD

CY2018

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

61000000

USD

CY2017

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

68000000

USD

CY2019

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

1200000

shares

CY2019

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y2M4D

CY2019

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

126.10

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

241.26

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3100000

shares

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

190.31

CY2018Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3700000

shares

CY2018Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

149.65

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

700000

shares

CY2019

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

306.61

CY2019

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

CY2018

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P3Y8M12D

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

355000000

USD

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

2000000.0

shares

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

145.37

CY2019

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P4Y11M4D

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

312000000

USD

CY2018Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1700000

shares

CY2018Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

183.32

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

600000

shares

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

305.88

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

800000

shares

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

153.79

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

100000

shares

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

242.38

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1400000

shares

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

242.47

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0269

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0290

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0231

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2500

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.3000

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.3200

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0100

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0130

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0160

CY2017

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

68.66

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

55.48

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

40.88

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

305.88

CY2018

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

233.73

CY2017

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

174.44

CY2019Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-01-29

CY2019Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-03-18

CY2019Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-03-29

CY2019Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

206000000

USD

CY2019Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-04-23

CY2019Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-06-10

CY2019Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-06-25

CY2019Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

206000000

USD

CY2019Q3

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-07-23

CY2019Q3

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-09-10

CY2019Q3

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-09-25

CY2019Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q3

us-gaap

Payments Of Dividends

PaymentsOfDividends

204000000

USD

CY2019Q4

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-10-22

CY2019Q4

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-12-05

CY2019Q4

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-12-20

CY2019Q4

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q4

us-gaap

Payments Of Dividends

PaymentsOfDividends

202000000

USD

CY2018Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2018-01-30

CY2018Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2018-03-09

CY2018Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2018-03-23

CY2018Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.75

CY2018Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

192000000

USD

CY2018Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2018-04-24

CY2018Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2018-06-08

CY2018Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2018-06-25

CY2018Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.75

CY2018Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

196000000

USD

CY2018Q3

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2018-07-24

CY2018Q3

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2018-09-10

CY2018Q3

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2018-09-25

CY2018Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.75

CY2018Q3

us-gaap

Payments Of Dividends

PaymentsOfDividends

195000000

USD

CY2018Q4

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2018-10-30

CY2018Q4

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2018-12-05

CY2018Q4

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2018-12-21

CY2018Q4

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.75

CY2018Q4

us-gaap

Payments Of Dividends

PaymentsOfDividends

193000000

USD

CY2017Q4

antm

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

USD

CY2019

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

6300000

shares

CY2018

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

6800000

shares

CY2019

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

268.65

CY2018

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

248.34

CY2019

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1701000000

USD

CY2018

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1685000000

USD

CY2019Q4

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

3792000000

USD

CY2018Q4

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

5493000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

720000000

USD

CY2019Q4

antm

Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

1000000

USD

CY2018Q4

antm

Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

1000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities

2000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities

2000000

USD

CY2019

us-gaap

Unrealized Gain Loss On Cash Flow Hedging Instruments

UnrealizedGainLossOnCashFlowHedgingInstruments

-331000000

USD

CY2018Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

173000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

44000000

USD

CY2018Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

371000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

676000000

USD

CY2018Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

-198000000

USD

CY2019Q4

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-155000000

USD

CY2018Q4

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

39000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

521000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-159000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities

3000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities

3000000

USD

CY2018

us-gaap

Unrealized Gain Loss On Cash Flow Hedging Instruments

UnrealizedGainLossOnCashFlowHedgingInstruments

-311000000

USD

CY2019Q4

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

69000000

USD

CY2018Q4

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

65000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-262000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-246000000

USD

CY2019Q4

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-734000000

USD

CY2018Q4

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-751000000

USD

CY2019Q4

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

1000000

USD

CY2018Q4

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

1000000

USD

CY2019Q4

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-188000000

USD

CY2018Q4

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-193000000

USD

CY2019Q4

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

547000000

USD

CY2018Q4

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

559000000

USD

CY2019Q4

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-25000000

USD

CY2018Q4

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-58000000

USD

CY2019Q4

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

19000000

USD

CY2018Q4

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

34000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

2000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

6000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

4000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

18000000

USD

CY2019Q4

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-3000000

USD

CY2018Q4

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-3000000

USD

CY2019Q4

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

1000000

USD

CY2018Q4

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

1000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Credit Losses Recognized In Earnings Period Increase Decrease

OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsPeriodIncreaseDecrease

0

USD

CY2018

us-gaap

Other Than Temporary Impairment Credit Losses Recognized In Earnings Period Increase Decrease

OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsPeriodIncreaseDecrease

2000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-296000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-986000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

695000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-465000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

280000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

15000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

-47000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

107000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

680000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

-418000000

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

173000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Credit Losses Recognized In Earnings Period Increase Decrease

OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsPeriodIncreaseDecrease

-4000000

USD

CY2019

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

-16000000

USD

CY2018

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

37000000

USD

CY2017

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

-65000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-26000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

90000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-51000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

CY2018

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-1000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

3000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

690000000

USD

CY2018

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-474000000

USD

CY2017

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

166000000

USD

CY2017

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

275000000

USD

CY2019

us-gaap

Ceded Premiums Written

CededPremiumsWritten

45000000

USD

CY2019

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

45000000

USD

CY2018

us-gaap

Ceded Premiums Written

CededPremiumsWritten

51000000

USD

CY2019

us-gaap

Direct Premiums Written

DirectPremiumsWritten

93953000000

USD

CY2019

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

93505000000

USD

CY2018

us-gaap

Direct Premiums Written

DirectPremiumsWritten

84835000000

USD

CY2018

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

85213000000

USD

CY2017

us-gaap

Direct Premiums Written

DirectPremiumsWritten

83974000000

USD

CY2017

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

83418000000

USD

CY2019

us-gaap

Assumed Premiums Written

AssumedPremiumsWritten

822000000

USD

CY2019

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

713000000

USD

CY2018

us-gaap

Assumed Premiums Written

AssumedPremiumsWritten

264000000

USD

CY2018

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

259000000

USD

CY2017

us-gaap

Assumed Premiums Written

AssumedPremiumsWritten

275000000

USD

CY2018

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

51000000

USD

CY2017

us-gaap

Ceded Premiums Written

CededPremiumsWritten

44000000

USD

CY2017

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

45000000

USD

CY2019

us-gaap

Premiums Written Net

PremiumsWrittenNet

94730000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2018

us-gaap

Premiums Written Net

PremiumsWrittenNet

85048000000

USD

CY2018

us-gaap

Premiums Earned Net

PremiumsEarnedNet

85421000000

USD

CY2017

us-gaap

Premiums Written Net

PremiumsWrittenNet

84205000000

USD

CY2017

us-gaap

Premiums Earned Net

PremiumsEarnedNet

83648000000

USD

CY2019

antm

Percentage Of Amount Assumed To Net Premiums Written

PercentageOfAmountAssumedToNetPremiumsWritten

0.009

CY2019

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.008

CY2018

antm

Percentage Of Amount Assumed To Net Premiums Written

PercentageOfAmountAssumedToNetPremiumsWritten

0.003

CY2018

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.003

CY2017

antm

Percentage Of Amount Assumed To Net Premiums Written

PercentageOfAmountAssumedToNetPremiumsWritten

0.003

CY2017

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.003

CY2019

us-gaap

Premiums Written Net

PremiumsWrittenNet

94730000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2017

us-gaap

Premiums Earned Net

PremiumsEarnedNet

83648000000

USD

CY2018

us-gaap

Premiums Written Net

PremiumsWrittenNet

85048000000

USD

CY2018

us-gaap

Premiums Earned Net

PremiumsEarnedNet

85421000000

USD

CY2017

us-gaap

Premiums Written Net

PremiumsWrittenNet

84205000000

USD

CY2019

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

589000000

USD

CY2018

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

219000000

USD

CY2017

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

217000000

USD

CY2019

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

57000000

USD

CY2018

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

73000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

81254000000

USD

CY2018

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

71749000000

USD

CY2017

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

72135000000

USD

CY2017

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

116000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2018

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

71895000000

USD

CY2017

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

72236000000

USD

CY2019Q4

us-gaap

Assumed Liability For Unpaid Claims And Claims Adjustment Expense

AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

213000000

USD

CY2018Q4

us-gaap

Assumed Liability For Unpaid Claims And Claims Adjustment Expense

AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

50000000

USD

CY2019

antm

Assumed Unearned Income

AssumedUnearnedIncome

114000000

USD

CY2018

antm

Assumed Unearned Income

AssumedUnearnedIncome

6000000

USD

CY2019Q4

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

11000000

USD

CY2018Q4

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

17000000

USD

CY2019Q4

antm

Assumed Premiums Receivable

AssumedPremiumsReceivable

35000000

USD

CY2018Q4

antm

Assumed Premiums Receivable

AssumedPremiumsReceivable

37000000

USD

CY2019

us-gaap

Operating Lease Cost

OperatingLeaseCost

198000000

USD

CY2019

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

46000000

USD

CY2019

us-gaap

Sublease Income

SubleaseIncome

16000000

USD

CY2019

us-gaap

Lease Cost

LeaseCost

228000000

USD

CY2019

us-gaap

Operating Lease Payments

OperatingLeasePayments

176000000

USD

CY2019

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

112000000

USD

CY2019Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P6Y

CY2019Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0409

CY2018

us-gaap

Lease And Rental Expense

LeaseAndRentalExpense

207000000

USD

CY2017

us-gaap

Lease And Rental Expense

LeaseAndRentalExpense

205000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

172000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

149000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

136000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

116000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

87000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

135000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

795000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

155000000

USD

CY2019Q4

us-gaap

Operating Leases Future Minimum Payments Due

OperatingLeasesFutureMinimumPaymentsDue

640000000

USD

CY2019Q4

us-gaap

Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1

LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1

P12Y

CY2019

us-gaap

Lessee Operating Lease Lease Not Yet Commenced Description

LesseeOperatingLeaseLeaseNotYetCommencedDescription

are expected to commence on various dates during 2020 and 2021 when the construction is complete and we take possession of the buildings.

CY2019Q4

antm

Lessee Operating Lease Lease Not Yet Commenced Expense

LesseeOperatingLeaseLeaseNotYetCommencedExpense

394000000

USD

CY2019

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

255500000

shares

CY2018

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

258100000

shares

CY2017

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

261500000

shares

CY2019

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

4800000

shares

CY2018

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

6100000

shares

CY2017

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

6300000

shares

CY2019

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

260300000

shares

CY2018

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

264200000

shares

CY2017

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

267800000

shares

CY2019

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

600000

shares

CY2017

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

400000

shares

CY2018

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

300000

shares

CY2017

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

400000

shares

CY2018Q2

us-gaap

Stock Issued During Period Shares New Issues

StockIssuedDuringPeriodSharesNewIssues

6000000.0

shares

CY2019

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

200000

shares

CY2019

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

3

segment

CY2019

us-gaap

Concentration Risk Percentage1

ConcentrationRiskPercentage1

0.207

CY2018

us-gaap

Concentration Risk Percentage1

ConcentrationRiskPercentage1

0.198

CY2017

us-gaap

Concentration Risk Percentage1

ConcentrationRiskPercentage1

0.178

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2019

us-gaap

Operating Income Loss

OperatingIncomeLoss

5999000000

USD

CY2019

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

675000000

USD

CY2018

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

91341000000

USD

CY2018

us-gaap

Operating Income Loss

OperatingIncomeLoss

5426000000

USD

CY2018

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

652000000

USD

CY2017

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

89061000000

USD

CY2017

us-gaap

Operating Income Loss

OperatingIncomeLoss

4175000000

USD

CY2017

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

601000000

USD

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2018

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

91341000000

USD

CY2017

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

89061000000

USD

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2018

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

91341000000

USD

CY2017

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

89061000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2018

us-gaap

Net Investment Income

NetInvestmentIncome

970000000

USD

CY2017

us-gaap

Net Investment Income

NetInvestmentIncome

867000000

USD

CY2019

antm

Netrealizedlossesgainsonfinancialinstruments

114000000

USD

CY2018

antm

Netrealizedlossesgainsonfinancialinstruments

-180000000

USD

CY2017

antm

Netrealizedlossesgainsonfinancialinstruments

145000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

47000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

26000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

33000000

USD

CY2019

us-gaap

Revenues

104213000000

USD

CY2018

us-gaap

Revenues

92105000000

USD

CY2017

us-gaap

Revenues

90040000000

USD

CY2019Q2

us-gaap

Revenues

25466000000

USD

CY2019Q3

us-gaap

Revenues

26674000000

USD

CY2019Q4

us-gaap

Revenues

27407000000

USD

CY2019Q4

us-gaap

Statutory Accounting Practices Statutory Capital And Surplus Required

StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired

5500000000

USD

CY2018Q4

us-gaap

Statutory Accounting Practices Statutory Capital And Surplus Required

StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired

4800000000

USD

CY2019

us-gaap

Operating Income Loss

OperatingIncomeLoss

5999000000

USD

CY2018

us-gaap

Operating Income Loss

OperatingIncomeLoss

5426000000

USD

CY2017

us-gaap

Operating Income Loss

OperatingIncomeLoss

4175000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2018

us-gaap

Net Investment Income

NetInvestmentIncome

970000000

USD

CY2017

us-gaap

Net Investment Income

NetInvestmentIncome

867000000

USD

CY2019

antm

Netrealizedlossesgainsonfinancialinstruments

114000000

USD

CY2018

antm

Netrealizedlossesgainsonfinancialinstruments

-180000000

USD

CY2017

antm

Netrealizedlossesgainsonfinancialinstruments

145000000

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

47000000

USD

CY2018

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

26000000

USD

CY2017

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

33000000

USD

CY2019

us-gaap

Interest Expense

InterestExpense

746000000

USD

CY2018

us-gaap

Interest Expense

InterestExpense

753000000

USD

CY2017

us-gaap

Interest Expense

InterestExpense

739000000

USD

CY2019

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

338000000

USD

CY2018

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

358000000

USD

CY2017

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

169000000

USD

CY2019

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-2000000

USD

CY2018

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-11000000

USD

CY2017

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-282000000

USD

CY2019

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

5985000000

USD

CY2018

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

5068000000

USD

CY2017

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

3964000000

USD

CY2019Q1

us-gaap

Revenues

24666000000

USD

CY2019Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

4.44

CY2019Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

4.64

CY2019Q4

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

3.69

CY2019Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

5.91

CY2019Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.36

CY2019Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.55

CY2019Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1945000000

USD

CY2019Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1453000000

USD

CY2019Q3

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1489000000

USD

CY2019Q4

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1098000000

USD

CY2019Q1

us-gaap

Net Income Loss

NetIncomeLoss

1551000000

USD

CY2019Q2

us-gaap

Net Income Loss

NetIncomeLoss

1139000000

USD

CY2019Q3

us-gaap

Net Income Loss

NetIncomeLoss

1183000000

USD

CY2019Q4

us-gaap

Net Income Loss

NetIncomeLoss

934000000

USD

CY2019Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

6.03

CY2019Q4

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

3.62

CY2018Q1

us-gaap

Revenues

22537000000

USD

CY2018Q2

us-gaap

Revenues

22944000000

USD

CY2018Q3

us-gaap

Revenues

23251000000

USD

CY2018Q4

us-gaap

Revenues

23373000000

USD

CY2018Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1780000000

USD

CY2018Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1504000000

USD

CY2018Q3

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1242000000

USD

CY2018Q4

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

542000000

USD

CY2018Q1

us-gaap

Net Income Loss

NetIncomeLoss

1312000000

USD

CY2018Q2

us-gaap

Net Income Loss

NetIncomeLoss

1054000000

USD

CY2018Q3

us-gaap

Net Income Loss

NetIncomeLoss

960000000

USD

CY2018Q4

us-gaap

Net Income Loss

NetIncomeLoss

424000000

USD

CY2018Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

5.13

CY2018Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

4.07

CY2018Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

3.70

CY2018Q4

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

1.64

CY2018Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.99

CY2018Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

3.98

CY2018Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

3.62

CY2018Q4

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

1.61

Name	View Source	Status
0001156039-20-000003-index-headers.html	Edgar Link	pending
0001156039-20-000003-index.html	Edgar Link	pending
0001156039-20-000003.txt	Edgar Link	pending
0001156039-20-000003-xbrl.zip	Edgar Link	pending
antm-20191231.xsd	Edgar Link	pending
antm-2019123110kq42019.htm	Edgar Link	pending
antm-2019123110kq42019_htm.xml	Edgar Link	completed
antm-20191231_cal.xml	Edgar Link	unprocessable
antm-20191231_def.xml	Edgar Link	unprocessable
antm-20191231_lab.xml	Edgar Link	unprocessable
antm-20191231_pre.xml	Edgar Link	unprocessable
capturea01.jpg	Edgar Link	pending
exhibit1011-20191231fo.htm	Edgar Link	pending
exhibit1012-20191231fo.htm	Edgar Link	pending
exhibit106-20191231for.htm	Edgar Link	pending
exhibit21-20191231for1.htm	Edgar Link	pending
exhibit23-20191231for1.htm	Edgar Link	pending
exhibit311-20191231for.htm	Edgar Link	pending
exhibit312-20191231for.htm	Edgar Link	pending
exhibit321-20191231for.htm	Edgar Link	pending
exhibit322-20191231for.htm	Edgar Link	pending
exhibit48-20191231for1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2019 Form 10-K Financial Statement

#000115603920000003 Filed on February 19, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2019 Form 10-K Financial Statement

#000115603920000003 Filed on February 19, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv